Sources
Source catalog
A public catalog of papers, trials, laws, policy records, podcasts, documentaries, books, cultural sources, claim records, and reference pages.
Sources indexed815
Key people and institutions
These names are not endorsements. They are search anchors for modern history, research, policy, cultural scholarship, advocacy, guidelines, and public media context.
Howard Lotsof
1962 observation, advocacy, Dora Weiner Foundation, and patent history.
Search records →Deborah Mash
Human Ibogaine research, public interviews, and treatment-development history.
Search records →Kenneth Alper
Clinical literature, reviews, safety context, and history of Ibogaine research.
Search records →Stanley Glick
18-MC and related preclinical development history.
Search records →Giorgio Samorini
Public scholarship on Iboga cults, mythology, and early written records.
Search records →Dimitri Mugianis
Documentary, harm-reduction, and public conversation history.
Search records →ICEERS
Community engagement, conservation, policy, and stewardship context.
Search records →GITA
Global Iboga Therapy Alliance materials, guidelines, and public education history.
Search records →NIDA / FDA / ClinicalTrials.gov
Research, regulatory status, trial registration, and official public records.
Search records →Source types
Youtube Video274
Journalism242
Podcast Interview143
State Policy Coverage Row51
Policy Tracker Row18
Peer Reviewed Study16
Clinical Trial Registry9
History Topic9
Condition Evidence Template8
Company Release4
Confidence labels
Media metadata418
Primary-source record274
State policy coverage row51
Peer-reviewed paper12
History topic9
Registry record9
Evidence framework7
Peer-reviewed source6
Claim record4
Cultural source4
People, organizations, and companies
Source-labeled records for the figures and organizations that recur across the catalog, including modern-history advocates, drug-development companies, guideline bodies, and conservation voices.
PersonConfidence: Moderate
Activism history
Dana Beal
Beal is a central figure in the U.S. ibogaine underground and its decades of public advocacy for ibogaine as an addiction-interruption tool.
- Dana Beal is a longtime political activist who, through the group Cures-not-Wars, helped organize and publicize ibogaine as a proposed treatment for opioid dependence from the 1980s onward.
- He is frequently described in journalism and reference sources as an ibogaine activist rather than a researcher or clinician.
- His advocacy is part of the movement history around ibogaine, separate from the peer-reviewed evidence and the safety literature.
What this does not prove: Activist advocacy is not clinical evidence; his role in ibogaine history says nothing about whether ibogaine is safe or effective.
Encyclopedic biography (secondary)
Search records →PersonConfidence: Moderate
Modern-history figure
Norma Lotsof
Norma Lotsof helped carry Howard Lotsof's ibogaine work forward, including through the Dora Weiner Foundation, and belongs in modern advocacy history.
- Norma Lotsof worked alongside Howard Lotsof and is associated with the Dora Weiner Foundation, the vehicle connected to Howard Lotsof's patents and advocacy.
- She is a figure in ibogaine advocacy history, not a clinical-research source.
What this does not prove: Stewardship of an advocate's legacy is not evidence about ibogaine's safety or effectiveness.
MAPS memorial context for Howard Lotsof (secondary)
Search records →OrganizationConfidence: Moderate
Guidelines and education
Global Ibogaine Therapy Alliance (GITA)
GITA is a widely cited source of ibogaine safety and clinical-guideline material that a safety-first reference should track.
- The Global Ibogaine Therapy Alliance (GITA) published Clinical Guidelines for Ibogaine-Assisted Treatment, a frequently cited document in ibogaine safety discussion.
- Those clinical guidelines emphasize cardiac screening, medical monitoring, exclusion criteria, and emergency readiness.
- IbogaBase describes GITA guidelines as source material, not as an IbogaBase-endorsed or IbogaBase-published protocol.
What this does not prove: Published guidelines are source material describing risk-management practice; they are not IbogaBase endorsement, not proof of efficacy, and not a protocol to follow.
GITA clinical guidelines (org statement)
Search records →CompanyConfidence: Moderate
Commercial development
atai Life Sciences
atai is a major psychedelic biotech whose ibogaine and noribogaine ventures shape the commercial and analog-development conversation.
- atai Life Sciences is a psychedelic biotech that, in January 2020, announced joint ventures with DemeRx to develop ibogaine and noribogaine for opioid use disorder.
- atai ibogaine activity is a commercial and drug-development signal within the wider psychedelic biotech field, not clinical proof.
- Business milestones and financing news are tracked separately from evidence and are not proof of effectiveness.
What this does not prove: Corporate investment, pipelines, and press releases do not establish clinical value, safety, or approval.
atai/DemeRx joint venture announcement (company release)
Search records →CompanyConfidence: Moderate
Analog development
Savant HWP
Savant HWP is central to the 18-MC development history in the ibogaine-analog lane.
- Savant HWP is the company associated with clinical-stage development of 18-MC (18-methoxycoronaridine), an ibogaine analog first characterized by Stanley Glick and Martin Kuehne.
- The Savant HWP 18-MC program is part of the analog-development history, distinct from ibogaine itself.
- Preclinical and early-stage analog work is not proof of human clinical benefit.
What this does not prove: Analog-development history does not make an analog interchangeable with iboga or ibogaine, and does not establish human efficacy.
Alper KR, Ibogaine: a review (secondary review, PubMed)
Search records →OrganizationConfidence: Moderate
Conservation and stewardship
Yann Guignon / Blessings of the Forest
Blessings of the Forest, associated with Yann Guignon, is a visible voice on Gabonese iboga conservation, cultivation, traceability, and benefit-sharing.
- Blessings of the Forest, a Gabon-focused initiative associated with Yann Guignon, works on iboga conservation, sustainable cultivation, traceability, and benefit-sharing.
- Its work is framed as conservation and stewardship, addressing wild-harvest pressure and access-and-benefit-sharing under the Nagoya Protocol.
- IbogaBase cites Blessings of the Forest as a conservation voice, not as a lineage or ceremonial authority.
What this does not prove: Conservation advocacy does not confer lineage authority and is not a claim about ceremonial knowledge or medical outcomes.
ICEERS Iboga community engagement report (secondary)
Search records →Conservation, sourcing, and benefit-sharing
Iboga accuracy depends on conservation and legal sourcing, not only clinical data. Public sources document wild-harvest pressure on Tabernanthe iboga in Gabon, cultivation efforts, and traceability of plant material from forest to product. Access-and-benefit-sharing under the Nagoya Protocol is the concrete legal instrument for Gabonese and community benefit, alongside conservation groups such as Blessings of the Forest. A "sustainable" or "ethical" sourcing label is a claim until traceability, current legal documentation, and benefit-sharing are shown.
Texas ibogaine funding, in primary-source terms
Texas Senate Bill 2308 (89th Legislature, 2025), authored by State Senator Tan Parker, directed a state-funded ibogaine clinical-research effort. In December 2025 the University of Texas Medical Branch (UTMB), with UTHealth Houston, was awarded $50 million by the state to lead ibogaine clinical trials. A funding appropriation and a trial program are not FDA approval, not treatment access, and not proof of effectiveness.
Mid-century and historical sources
Ibogaine's commercial and pharmacological history predates modern research. A Tabernanthe extract was sold in France as Lambarene, and the company CIBA studied ibogaine and related alkaloids in the mid-twentieth century. These are historical commercial and pharmacology records, not evidence of modern safety or effectiveness.
Coverage and known gaps
Completeness is part of trust. IbogaBase tracks a fixed set of canonical topics across history, culture, safety, law, evidence, and media, and shows which are covered, thin, or still being sourced. Where a topic cannot yet be sourced to a strong record, it is held out of public copy rather than filled with plausible-sounding text.
required history, culture, safety, law, and media coverage
visible or searchable in the current site
known gaps or items needing stronger sources
public records indexed for search
This coverage audit is a reader-facing view of the same obligations tracked in the IbogaBase integrity report. It flags what has been checked and what is still wanted; it is not legal, medical, or cultural certification.
Wanted sources
These are the gaps that would most improve the public reference.
- Named medical reviewers: Cardiology, addiction medicine, emergency medicine, pharmacology, and psychiatry reviewers who are willing to be listed.
- Named cultural advisors: Gabonese, Bwiti/Bwete-linked, conservation, and stewardship advisors only when they consent to public naming.
- Adverse-event case material: Peer-reviewed case reports, agency records, and serious journalism with enough detail to separate signal from speculation.
- State-policy primary records: Bill text, fiscal notes, committee reports, hearing video, agency pages, and final signed law when available.
- Primary media links: Original podcast, YouTube, documentary, book, and interview pages rather than reposted summaries.
Catalog preview
Source type: StudyConfidence: High
Magnesium-ibogaine therapy in veterans with traumatic brain injuries
Prospective open-label observational study of 30 male special-operations veterans who independently received magnesium-ibogaine treatment at Ambio Life Sciences in Mexico, with Stanford assessments before and after. The paper reports large short-term improvements and no unexpected serious adverse events, while stating that controlled clinical trials are needed.
Source type: StudyConfidence: High
Magnesium-ibogaine therapy effects on cortical oscillations and neural complexity in veterans with traumatic brain injury
Follow-up Nature Mental Health article on EEG and neural-complexity measures in the same broad magnesium-ibogaine veteran TBI research lane. It reports neurophysiological changes after treatment and states that controlled trials are needed to confirm findings.
Source type: StudyConfidence: Low
Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis
Two-patient case report involving Ambio-affiliated authors and Ambio treatment records. Treat as preliminary case-report evidence with prominent conflict-of-interest and funder-involvement labels, not proof of efficacy.
Source type: StudyConfidence: Moderate
Mapping Ibogaine Neural Dynamics in Opioid Use Disorder
ClinicalTrials.gov lists NCT07226570 as recruiting. A registry listing identifies a study and status; it is not safety, efficacy, approval, or treatment-access proof.
Source type: StudyConfidence: High
Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Challenges
Use as a synthesis source for therapeutic-potential claims, cardiac safety limits, and translational caution. It supports safety-first interpretation, not efficacy certainty.
Source type: StudyConfidence: Low
Ibogaine for the treatment of Parkinson's disease: a case report
Track as exciting but very preliminary. One patient, low-dose course, validated PD instruments, no adverse events recorded, sleep worsened; not efficacy proof.
Source type: StudyConfidence: High
Accelerated recovery using magnesium ibogaine: subjective experience analysis
Qualitative analysis from the 30-person MISTIC veteran cohort; interpret alongside open-label design limits.
Source type: StudyConfidence: High
Mystical experiences during magnesium-Ibogaine associated with PTSD symptom improvements in veterans
Track as 30-male-veteran secondary analysis from MISTIC; association does not prove mechanism or general efficacy.
Source type: StudyConfidence: High
Magnesium-ibogaine therapy effects on cortical oscillations and neural complexity
Track as follow-on analysis from the veteran TBI research line.
Source type: StudyConfidence: High
Efficient and modular synthesis of ibogaine and related alkaloids
Important for supply, analog research, and non-plant-derived chemistry coverage.
Source type: StudyConfidence: Moderate
A study of oral ibogaine in opioid withdrawal
Track recruitment/status, sponsor, eligibility criteria, and posted results.
Source type: StudyConfidence: High
Veterans Say an Illegal Psychedelic Drug Is Helping Them. Now Mississippi Wants to Study Ibogaine. - Mississippi Free Press
Research source from Mississippi Free Press. Study design, sample size, limitations, and safety signals matter.
Source type: CultureConfidence: High
Ibogaine’s Surge in Popularity Could Be a Huge Loss for the Gabonese People Unless We Shift Course - psychedelicalpha.com
Culture or stewardship source from psychedelicalpha.com. Outsider summaries require humility and source awareness.
Source type: MediaConfidence: High
Ibogaine and addiction in the animal model, a systematic review and meta-analysis - Nature
News or commentary from Nature. Use it to understand public discussion and timing; verify important claims against primary sources.
Source type: StudyConfidence: High
Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis - Frontiers
Research source from Frontiers. Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: High
Induction of insulin secretion by an aqueous extract of Tabernanhte iboga Baill. (Apocynaceae) in rat pancreatic islets of Langerhans - ScienceDirect
Research source from ScienceDirect. Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: High
Study Identifies Compounds Similar to Ibogaine That May Improve Treatment of Opioid Addiction - Association of American Universities (AAU)
Research source from Association of American Universities (AAU). Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: High
Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias - Wiley Online Library
Research source from Wiley Online Library. Study design, sample size, limitations, and safety signals matter.
Source type: MediaConfidence: High
A Texas hallucinogen hub? $100 million for ibogaine testing brings leading firm to Austin - Yahoo
News or commentary from Yahoo. Use it to understand public discussion and timing; verify important claims against primary sources.
Source type: MediaConfidence: Moderate
Ibogaine Detox Mexico: Powerful $6,000 Opioid Treatment
Covers Ibogaine Detox Mexico: Powerful $6,000 Opioid Treatment. This is a media source, not medical evidence.
Source type: LawConfidence: High
Bush: Ibogaine saved my family - A Mississippi veteran’s perspective - tallahatchienews.ms
Law or policy source from tallahatchienews.ms. Read the exact source before drawing legal conclusions.
Source type: StudyConfidence: High
Response to Luz & Mash on cardiac toxicity of ibogaine - Schellekens - 2022 - Addiction - Wiley Online Library
Research source from Wiley Online Library. Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: High
Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series - Frontiers
Research source from Frontiers. Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: High
Traditional opioid treatments are inadequate, but ibogaine research is an overpriced boondoggle - The Courier-Journal
Research source from The Courier-Journal. Study design, sample size, limitations, and safety signals matter.
Source type: LawConfidence: High
Colorado lawmakers approve Ibogaine research bill - CBS News
Law or policy source from CBS News. Read the exact source before drawing legal conclusions.
Source type: StudyConfidence: High
Kentucky Republican proposes studying psychedelic drug ibogaine to curb addiction - Hanford Sentinel
Research source from Hanford Sentinel. Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: High
A Case of QT Prolongation and Torsades de Pointes Caused by Ibogaine Toxicity - ScienceDirect.com
Research source from ScienceDirect.com. Study design, sample size, limitations, and safety signals matter.
Source type: MediaConfidence: High
Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders | npj Mental Health Research - Nature
News or commentary from Nature. Use it to understand public discussion and timing; verify important claims against primary sources.
Source type: MediaConfidence: High
US speeds up research into mind-altering drugs — including mysterious ‘ibogaine’ - Nature
News or commentary from Nature. Use it to understand public discussion and timing; verify important claims against primary sources.
Source type: MediaConfidence: High
Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models - Nature
Book or bibliography source from Nature. Interpret claims according to source type and evidence quality.
Source type: StudyConfidence: Moderate
New Frontiers in Psychedelic Research: Iboga Microdosing with Dr. Burton J. Tabaac & Teresa Yung
Research source from Psychedelic Vantage. Study design, sample size, limitations, and safety signals matter.
Source type: LawConfidence: High
Lawmakers hear from veterans, medical professionals as they consider the efficacy of Ibogaine - Magnolia Tribune
Law or policy source from Magnolia Tribune. Read the exact source before drawing legal conclusions.
Source type: StudyConfidence: High
University of Texas Medical Branch to receive $50M to study psychedelic ibogaine - The Daily News | Texas' Oldest Newspaper
Research source from The Daily News | Texas' Oldest Newspaper. Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: Moderate
#511: Hamilton Morris on Iboga, 5-MeO-DMT, The Power of Ritual, New Frontiers in Psychedelics, Excellent Problems to | The Tim Ferriss Show
Research source from 5 minute podcast summaries of: Tim Ferriss, Hidden Brain, Sam Harris, Lex Fridman, Jordan Peterson. Study design, sample size, limitations, and safety signals matter.
Source type: MediaConfidence: Moderate
Hamilton Morris chillstep—ibogaine
Covers Hamilton Morris chillstep—ibogaine. This is a media source, not medical evidence.
Source type: PrimaryConfidence: High
Psychedelic drug ibogaine hailed as healing. U.S. patients ask why it’s illegal. - The Washington Post
Company, patent, or biotech-field source from The Washington Post. Commercial claims need independent verification.
Source type: MediaConfidence: Moderate
Ibogaine as a reset for addiction and weed policy
Covers Ibogaine as a reset for addiction and weed policy. This is a media source, not medical evidence.
Source type: StudyConfidence: High
Sustained abstinence in severe ketamine use disorder following ibogaine treatment - Frontiers
Research source from Frontiers. Study design, sample size, limitations, and safety signals matter.
Source type: MediaConfidence: High
Psychoactive drug ibogaine effectively treats traumatic brain injury in special ops military vets - Stanford Medicine
News or commentary from Stanford Medicine. Use it to understand public discussion and timing; verify important claims against primary sources.
Source type: StudyConfidence: High
Texas to launch independent psychedelic study after drug companies miss mark - FOX 7 Austin
Research source from FOX 7 Austin. Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: High
Legislative updates in Mississippi, West Virginia, Oregon, and New Hampshire; Fast-tracked federal approval of Compass's synthetic psilocybin was vetoed; Federal bill proposes VA study psychedelics - The Microdose
Research source from The Microdose. Study design, sample size, limitations, and safety signals matter.
Source type: MediaConfidence: High
Psychedelic Stocks Rally After Trump’s Executive Order - Forbes
News or commentary from Forbes. Use it to understand public discussion and timing; verify important claims against primary sources.
Source type: StudyConfidence: High
Toward a nuanced framework for the medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology.
Research source from Expert opinion on drug discovery. Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: High
Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain-Related Outcomes Among People With Non-Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial.
Research source from Drug and alcohol review. Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: High
Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives.
Research source from Journal of clinical psychopharmacology. Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: High
Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.
Research source from JAMA psychiatry. Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: High
The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review.
Research source from Journal of psychopharmacology (Oxford, England). Study design, sample size, limitations, and safety signals matter.
Source type: StudyConfidence: High
Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain.
Research source from Journal of pharmaceutical and biomedical analysis. Study design, sample size, limitations, and safety signals matter.